Payment overview · 2025
General Payments
$341.09
17 reported records · 11 companies
Healthcare provider profile · identity verified
Aurelio Ibarra, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DALLAS, TX · NPI 1588994693
Verified facts
What the public records show
CMS Open Payments records show Aurelio Ibarra, M.D. received $341.09 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $124.82 | 36.6% | 5 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $46.29 | 13.6% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.36 | 10.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.33 | 7.1% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $18.95 | 5.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.71 | 4.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.95 | 4.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.94 | 4.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.37 | 4.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $13.71 | 4.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.66 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.09 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $124.82 | 5 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $79.41 | 3 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $79.41 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $73.87 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $70.64 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $46.29 | 2 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $46.29 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 66 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 849 | 292 |
| Lisinopril | Lisinopril | 775 | 259 |
| Metformin Hcl | Metformin Hcl | 739 | 253 |
| Gabapentin | Gabapentin | 487 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 445 | 166 |
| Simvastatin | Simvastatin | 362 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 109 |
| Alendronate Sodium | Alendronate Sodium | 273 | 117 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 94 |
| Celecoxib | Celecoxib | 256 | 127 |
| Losartan Potassium | Losartan Potassium | 252 | 89 |
| Famotidine | Famotidine | 247 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 83 |
| Omeprazole | Omeprazole | 221 | 80 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 220 | 163 |
| Glipizide | Glipizide | 211 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 114 |
| Trazodone Hcl | Trazodone Hcl | 194 | 74 |
| Furosemide | Furosemide | 190 | 85 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 187 | 103 |
| Meloxicam | Meloxicam | 167 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 165 | 85 |
| Jardiance | Empagliflozin | 157 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 55 |
| Ibuprofen | Ibuprofen | 138 | 71 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 129 | 84 |
| Mometasone Furoate | Mometasone Furoate | 128 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 42 |
| Ezetimibe | Ezetimibe | 115 | 42 |
| Ciclopirox | Ciclopirox | 112 | 65 |
| Meclizine Hcl | Meclizine Hcl | 112 | 68 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 107 | 60 |
| Tradjenta | Linagliptin | 106 | 37 |
| Carvedilol | Carvedilol | 105 | 47 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 98 | 73 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 36 |
| Ozempic | Semaglutide | 92 | 21 |
| Finasteride | Finasteride | 90 | 40 |
| Acarbose | Acarbose | 87 | 32 |
| Naproxen | Naproxen | 86 | 35 |
| Nystatin | Nystatin | 84 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 45 |
| Azithromycin | Azithromycin | 77 | 62 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 37 |
| Mounjaro | Tirzepatide | 71 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 69 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 19 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 58 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 22 |
| Mupirocin | Mupirocin | 56 | 37 |
| Donepezil Hcl | Donepezil Hcl | 55 | 26 |
| Farxiga | Dapagliflozin Propanediol | 55 | 19 |
| Montelukast Sodium | Montelukast Sodium | 55 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 20 |
| Eliquis | Apixaban | 52 | 21 |
| Indomethacin | Indomethacin | 50 | 27 |
| Clonidine Hcl | Clonidine Hcl | 49 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 33 |
| Allopurinol | Allopurinol | 46 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 45 | 22 |
| Hydrocortisone | Hydrocortisone | 44 | 25 |
| Fluconazole | Fluconazole | 43 | 24 |
| Trulicity | Dulaglutide | 41 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 15 |
| Sertraline Hcl | Sertraline Hcl | 39 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 14 |
| Advocate Pen Needles | Pen Needle, Diabetic | 36 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 19 |
| Prednisone | Prednisone | 36 | 24 |
| Amoxicillin | Amoxicillin | 35 | 28 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 34 | 31 |
| Nitroglycerin | Nitroglycerin | 33 | 22 |
| Pregabalin | Pregabalin | 33 | 11 |
| Ketoconazole | Ketoconazole | 32 | 12 |
| Myrbetriq | Mirabegron | 32 | 13 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 32 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 14 |
| Glimepiride | Glimepiride | 31 | 13 |
| Glyburide | Glyburide | 31 | 17 |
| Baclofen | Baclofen | 30 | 14 |
| Fenofibrate | Fenofibrate | 30 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 27 |
| Gemfibrozil | Gemfibrozil | 29 | 12 |
| Januvia | Sitagliptin Phosphate | 29 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 15 |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | 18 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Lactulose | Lactulose | 28 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 11 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | 11 |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.09 · 17 records | PFIZER INC. | ABRYSVO, BEYFORTUS, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DAYBUE, Doc Band, ENFLONSIA, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, JARDIANCE, Kerendia, Korlym, MENQUADFI, PENBRAYA, PREVNAR 20, TRUMENBA, TZIELD, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error